Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) was the target of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 10,541,776 shares, a growth of 19.3% from the January 29th total of 8,839,652 shares. Based on an average trading volume of 845,002 shares, the days-to-cover ratio is presently 12.5 days. Approximately 15.1% of the shares of the company are short sold. Approximately 15.1% of the shares of the company are short sold. Based on an average trading volume of 845,002 shares, the days-to-cover ratio is presently 12.5 days.

Inhibikase Therapeutics Price Performance

NASDAQ:IKT traded up $0.04 during mid-day trading on Wednesday, hitting $1.95. The company’s stock had a trading volume of 1,757,567 shares, compared to its average volume of 1,861,127. The firm has a market cap of $146.60 million, a P/E ratio of -5.00 and a beta of 0.76. Inhibikase Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $2.58. The company has a fifty day simple moving average of $1.77.

Analyst Ratings Changes

Several analysts have issued reports on IKT shares. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. HC Wainwright upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research report on Friday, December 26th. Wall Street Zen upgraded Inhibikase Therapeutics to a “sell” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Inhibikase Therapeutics has an average rating of “Buy”.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.